title: Effects of extracorporeal photoimmunotherapy on soluble IL-2Ralpha, TNF-RI, and CD8 in patients with steroid-resistant acute graft-versus-host disease.
abstract: Extracorporeal photoimmunotherapy (ECP) has been successfully used as adjunct treatment for steroid-resistant graft-versus-host disease (GvHD) after allogeneic stem cell transplantation. We serially investigated serum levels of soluble interleukin-2 receptor-alpha (sIL-2Ralpha), soluble tumor necrosis factor receptor I (sTNF-RI), and soluble CD8 (sCD8) in 19 patients with steroid-resistant acute GvHD before and after each ECP treatment. Highest levels of sIL-2Ralpha and sTNF-RI correlated with severe acute GvHD and infections. Despite an immediate sIL-2Ralpha and sTNF-RI decrease after each treatment cycle, a mean surge of sTNF-RI>sIL-2Ralpha during the first three ECP cycles was observed in infections. A delayed surge, i.e., after the third ECP cycle, of sIL-2Ralpha and elevated post-ECP sCD8 levels was observed in patients developing chronic GvHD. While levels of sIL-2Ralpha and sTNF-RI correlate with the severity of acute GvHD and infections during the early ECP treatment period, the recurring increase of post-ECP sCD8 possibly may serve as parameter for developing chronic GvHD.
authors.affiliation: Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, University of Vienna, Vienna, Austria.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Kokalj
authors.forename: Hildegard T
authors.initials: HT
authors.lastname: Greinix
authors.forename: Marina
authors.initials: M
authors.lastname: Ciovica
authors.forename: Harald
authors.initials: H
authors.lastname: Kittler
authors.forename: Peter
authors.initials: P
authors.lastname: Kalhs
authors.forename: Robert M
authors.initials: RM
authors.lastname: Knobler
authors.forename: Beatrix
authors.initials: B
authors.lastname: Volc-Platzer
mesh_terms: D000208:Acute Disease; D000328:Adult; D015703:Antigens, CD / Q000097:blood; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D016827:CD8 Antigens / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D053645:Interleukin-2 Receptor alpha Subunit; D008297:Male; D008875:Middle Aged; D010789:Phototherapy; D018123:Receptors, Interleukin / Q000097:blood; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood; D047888:Receptors, Tumor Necrosis Factor, Type I; D033581:Stem Cell Transplantation / Q000009:adverse effects
chemical_list: D015703:Antigens, CD; D016827:CD8 Antigens; C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D018123:Receptors, Interleukin; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I